Resumen
Objetivo: Describir la relación entre la glicación avanzada y el desarrollo de enfermedades cardiovasculares en pacientes con diabetes mellitus tipo 2 (DM2), enfatizando los mecanismos fisiopatológicos, los biomarcadores, los métodos de evaluación y las estrategias de prevención y tratamiento. Métodos: Se trata de una revisión integradora de la literatura realizada en las bases de datos MEDLINE/PubMed, LILACS, SciELO, Embase y Scopus. Se incluyeron estudios publicados, preferentemente, entre los años 2020 y 2025, en portugués, inglés o español. La selección de los estudios fue realizada por dos revisores independientes, seguida de un análisis descriptivo de la evidencia. Resultados/Discusión: La evidencia demuestra que los productos finales de glicación avanzada (AGEs) promueven la inflamación, el estrés oxidativo, la disfunción endotelial y el remodelado vascular, principalmente mediante la activación del eje AGE–RAGE, favoreciendo la aterosclerosis y un mayor riesgo cardiovascular. Biomarcadores como la Nε-carboximetillisina (CML), la hidroimidazolona-1 derivada del metilglioxal (MG-H1), el receptor soluble para los productos finales de glicación avanzada (sRAGE), el índice de glicación de la hemoglobina (HGI) y la autofluorescencia cutánea han mostrado potencial para la estratificación del riesgo cardiovascular. Sin embargo, su aplicación clínica aún presenta limitaciones relacionadas con la falta de estandarización de los métodos de evaluación y el predominio de estudios observacionales. Consideraciones finales: La glicación avanzada constituye un importante mecanismo asociado al riesgo cardiovascular en pacientes con DM2. No obstante, se requieren estudios prospectivos y protocolos estandarizados para validar la aplicación clínica de estos biomarcadores y ampliar su utilización en la prevención y el manejo de las complicaciones cardiovasculares.
Referencias
1. BANSAL S, et al. Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes. World Journal of Diabetes, 2023; 14(8): 1146-1162.
2. BENJAMIN EJ, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, 1994; 271(11): 840-844.
3. BOERSMA HE, et al. Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes. BMC Endocrine Disorders, 2021; 21(1): 14.
4. CHOI LS, et al. Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus. Heliyon, 2022; 8(6): e09571.
5. DE LA CRUZ-ARES S, et al. Endothelial dysfunction and advanced glycation end products in patients with newly diagnosed versus established diabetes: From the CORDIOPREV Study. Nutrients, 2020; 12(1):238..
6. DE VOS LC, et al. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014; 34(4):933-8.
7. DINESH SHAH A, et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. The Lancet, 2015; 385: S86.
8. DUQUE A, et al. Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications. World Journal of Diabetes, 2021; 12(6): 855-867.
9. GIGLIO RV, et al. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021; 1867(8): 166148.
10. GUPTA A, et al. Soluble receptor for advanced glycation end products and its role in cardiovascular risk assessment in hyperglycemia - A study in North India. Journal of Family Medicine and Primary Care, 2025; 14(4): 1325-1332.
11. HUXLEY RR, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. The American Journal of Cardiology, 2011; 108(1): 56-62.
12. KADOWAKI T, et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Diabetes, Obesity and Metabolism, 2022; 24(12): 2283-2296.
13. KANEKO H, et al. Fasting plasma glucose and subsequent cardiovascular disease among young adults: Analysis of a nationwide epidemiological database. Atherosclerosis, 2021.
14. KIM Y. Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies. Nutrients, 2023; 15(8): 2002.
15. LEE J, et al. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients, 2022; 14(15): 3086.
16. LI LY, et al. High serum levels of N-epsilon-carboxymethyllysine are associated with poor coronary collateralization in type 2 diabetic patients with chronic total occlusion of coronary artery. BMC Cardiovascular Disorders, 2022; 22(1): 282.
17. LIN Z, et al. Hemoglobin glycation index and cardiovascular outcomes in patients with diabetes and coronary artery disease: insights from a large cohort study. Nutrition & Diabetes, 2024; 14(1): 69.
18. LINKENS AMA, et al. Habitual Intake of Dietary Advanced Glycation End Products Is Not Associated with Arterial Stiffness of the Aorta and Carotid Artery in Adults: The Maastricht Study. The Journal of Nutrition, 2021; 151(7): 1886-1893.
19. MOVAHED MR, et al. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. International Journal of Cardiology, 2005; 105(3): 315-318.
20. NAKAMURA T, et al. Continuous low serum levels of advanced glycation end products and low risk of cardiovascular disease in patients with poorly controlled type 2 diabetes. Cardiovascular Diabetology, 2023; 22(1): 147.
21. OMACHI T, et al. Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study. Diabetes Therapy, 2024; 15(1): 111-126.
22. PLANAS A, et al. Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes. International Journal of Molecular Sciences, 2022; 23(11): 6234.
23. PINTO RS, et al. Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease. International Journal of Molecular Sciences, 2022; 23(5): 2404.
24. RAGAZZI E, et al. Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study. Frontiers in Endocrinology, 2023; 14: 1163554.
25. REUREAN-PINTILEI D, et al. Associations between Skin Autofluorescence Levels with Cardiovascular Risk and Diabetes Complications in Patients with Type 2 Diabetes. Biomedicines, 2024; 12(4): 890.
26. REUREAN-PINTILEI D, et al. Skin Autofluorescence as a Potential Adjunctive Marker for Cardiovascular Risk Assessment in Type 2 Diabetes: A Systematic Review. International Journal of Molecular Sciences, 2024; 25(7): 3889.
27. STIRBAN A, et al. Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins. Diabetes Care, 2013; 36(5): 1278-1282.
28. VAN DER BRUGGEN MM, et al. Plasma Reactive Dicarbonyls Are Not Independently Associated With Arterial Stiffness: The Maastricht Study. American Journal of Hypertension, 2025; 38(10): 777-787.
29. VEKIC J, et al. The Role of Advanced Glycation End Products on Dyslipidemia. Metabolites, 2023; 13(1): 77.
30. WANG Y, et al. Association between hemoglobin glycation index and 5-year major adverse cardiovascular events: the REACTION cohort study. Chinese Medical Journal, 2023; 136(20): 2468-2475.
31. WU C, et al. Glycemic variability of glycated hemoglobin in patients with type 2 diabetes mellitus and the risk of cardiovascular diseases: a latest systematic review and meta-analysis. Frontiers in Endocrinology, 2025; 16: 1698360.
32. XU S, et al. The hemoglobin glycation index predicts the risk of adverse cardiovascular events in coronary heart disease patients with type 2 diabetes mellitus. Frontiers in Cardiovascular Medicine, 2022; 9: 992252.
33. YOZGATLI K, et al. Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in type 2 diabetes mellitus. Diabetic Medicine, 2018; 35(9), 1242-1248.
